ARTICLE SUMMARY:
Using recently discovered regenerative techniques and an innovative bioreactor, Platelet BioGenesis is closing a weak link in our blood supply chain by offering on-demand production of platelets at affordable prices.
Platelets are essential for blood clotting and hemostasis, and their variable quality and availability can lead to deadly complications or disorders for vulnerable patients, particularly those undergoing cancer treatment, who are thrombocytopenic or victims of traumatic injury. These anucleate cells, however, are the weak link in our blood supply chain, due to their frustratingly short half-life and exacting storage requirements.
